ArticleOncogene2019

Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9.

Kathy-Ann Secker et al.PubMed ↗Publisher ↗

No numbers read from the abstract.